X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
VX-103 (MIMIX-flu vaccine ) were well tolerated, with no serious or severe adverse events. The overall rate of reported systemic events was favorable as compared to traditional vaccines delivered by needle and syringe.
Lead Product(s): MIMIX-flu Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: VX-103
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 14, 2022
Details:
In preclinical studies of MIMIX-Flu, combines GC’s commercial seasonal influenza vaccine antigen with Vaxess’s innovative MIMIX patch-based intradermal controlled release delivery system, have demonstrated dose sparing and improved immunogenicity.
Lead Product(s): VX103
Therapeutic Area: Infections and Infectious Diseases Product Name: MIMIX-Flu
Highest Development Status: IND EnablingProduct Type: Vaccine
Partner/Sponsor/Collaborator: GC Pharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 05, 2022
Details:
Funding will be used to integrate mRNA-based vaccines and gene modulators provided through a collaboration with the Santangelo Lab at Georgia Tech into MIMIX patches to improve the efficacy and administration of novel mRNA-based vaccines and other medical countermeasures.
Lead Product(s): mRNA-based COVID-19 vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Vaccine
Partner/Sponsor/Collaborator: National Science Foundation
Deal Size: $2.0 million Upfront Cash: Undisclosed
Deal Type: Funding January 22, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
